Journal of Cardiac Failure

The Journal of Cardiac Failure and the Heart Failure Society of America (HFSA) are proud to announce the launch of a new open-access journal, JCF-Intersections (JCF-I), in partnership with Elsevier. This new journal will join the JCF Family of Journals, led by the Journal of Cardiac Failure. JCF-Intersections will focus on the intersection of heart failure and other cardiovascular disciplines and specialties, with a strong emphasis on high quality science, and a commitment to diversity, equity, inclusion and mentorship, ensuring everyone's voice is heard and valued.

Will anti-inflammatory therapy be the next pillar for treating patients with HF? In this post-hoc analysis of the CORTAHF trial, in patients with acute HF and inflammatory activation, burst steroid administration was associated with improved symptoms and signs of congestion, which was additive to the effects of GDMT. Explore this research in #JCF to learn more about the results and potential mechanisms. #HFSA2024 ??https://bit.ly/3Y0l5yu

The primary results of the CARE-HK registry were just released for #HFSA2024! This registry aims to compare the treatment patterns around RAASi with treatment guidelines in patients with HF at high risk for hyperkalemia. Check out the rationale & design paper, out now in #JCF. ??https://bit.ly/3B9RGZS

??Out Now in #JCF: In July 2021, the Journal of Cardiac Failure implemented a double-blind review process hoping to reduce bias. What are initial observations? The analysis found that female first authorship steadily rose while female senior authorship remained fairly stable. Further, articles with a female senior author were significantly more likely to have a female first author. Overall, the investigators found that the double-blind review process increased gender diversity among first authors in this initial phase. Further work will be devoted to continuing to understand the implications over time. #HFSA2024. ??https://bit.ly/47J8wLa

An age-old hemodynamics debate: pressure or volume? While pressure-guided remote patient monitoring (RPM) devices are available, volume-based management is limited. We’re excited about this research on the safety and feasibility of the FIRE1 implantable IVC sensor, from #HFSA2024. In addition to safety, this novel device provided accurate IVC volume assessment (R2=0.99 with concurrent CT)! Out now in #JCF. ?? https://bit.ly/3TOMUr3

Palliative care should be integrated early in the trajectory of heart disease. Read about racial disparities, equality and timing of palliative care consultations in a large urban healthcare system! ???????????? How can we improve care for our patients? Read more to find out. ??https://bit.ly/3MGinb9

To bridge … or not to bridge? ?? Managing peri-procedure anticoagulation can be challenging in LVAD patients. Read about the KVAD study which explores the use of 4F-PCC for temporary warfarin reversal for invasive procedures in LVAD patients! Check out the accompanying editorials: ?? https://bit.ly/4e0ohzE ?? https://bit.ly/3AZOOyC

??The updated 2024 Heart Failure (HF) Epidemiology and Outcomes Statistics Report is now published in @JCardFail! HF-Stats 2024 provides updates to last year's inaugural report with key data and analysis about the state of HF in the U.S. and around the world. ?? Explore HF-Stats for the latest updates about: ??HF incidence, prevalence and lifetime risk estimates ??HF trends in the US and globally including HF hospitalization and mortality rates ??Disparities in social determinants of health and health inequities ??Current use of guideline-directed medical therapy ??Cost of HF-related treatment, and more! ??https://bit.ly/3zm6gwW

?? Only one out of every ten patients with HF were discharged on an SGLT2i from VA Hospitals from 2019-2022. However, prescription rates increased from 2% to 24% over the same period, with substantial variability across VA hospitals. Read about the factors associated with SGLT2i prescription rates in this month's #JCF issue. ??https://bit.ly/47rVoKf Also, check out the accompanying #PatientFocus article that breaks down this study’s findings for your patients! ??: https://bit.ly/4eoHhb9 Natasha Din - MD, MAS Ankeet S. Bhatt, MD, MBA Paul Heidenreich

?? Feeling lost in dealing with the evolving treatment options for hypertrophic cardiomyopathy? We have you covered with this review in the September issue of JCF! Brush up on medical management, septal-reduction, and the latest with myosin modulators here: https://bit.ly/3Tr7td6